PMC8007973_01
CT scan images of the large liver metastasis of a pancreatoblastoma (patient # 1) in a 33 year-old woman: before (A) and after six cycles (B) of FOLFIRINOX regimen: minor response; (C): Lolliplot of CTNNB1 gene showing the S37C mutation in exon 3.
fonc-11-564506-g0001.jpg
PMC8007973_01_fonc-11-564506-g0001.jpg
F1
On contrast-enhanced CT-scan, we observed a minor response for the main metastasis (from 120 to 95 mm; Figure 1B), and stabilization for the two other ones, thus defining a RECIST 1.1 stable disease.
PMC8007973_02
MRI images of liver metastases of our second case of pancreatoblastoma (patient # 2) before (A) and after four cycles (B) of FOLFIRINOX regimen: partial response.
fonc-11-564506-g0002.jpg
PMC8007973_02_fonc-11-564506-g0002.jpg
F2
April 2019 for gallbladder stones without any hepatic ultrasound abnormality. A CT-scan, performed as part of the assessment of a possible rheumatismal disease, showed a pancreatic tail tumor associated with multiple liver metastases confirmed by an abdominal MRI (Figure 2A). CT-scan and hepatic MRI performed after the fourth cycle showed a RECIST 1.1 partial response with a decrease of the maximal diameter of the pancreatic lesion from 44 to 23 mm and a decrease in number and size of all hepatic lesions that became infracentimetric (Figure 2B).
Genomic profile of the 5q22.2 chromosomal region showing the breakage in APC gene.
fonc-11-564506-g0003.jpg
PMC8007973_02_fonc-11-564506-g0003.jpg
F3
A deletion associated with a breakage targeting APC (5q22.2: Figure 3) was observed.